Nilotinib counteracts thioacetamide-induced hepatic oxidative stress and attenuates liver fibrosis progression

Fundamental and Clinical Pharmacology

Volumn 25, Issue 2, 2011, Pages 248-257

  Shaker, Mohamed E ^a   Salem, Hatem A ^a   Shiha, Gamal E ^b   Ibrahim, Tarek M ^a  

^a MANSOURA UNIVERSITY   (Egypt)

^b MANSOURA UNIVERSITY   (Egypt)

Author keywords

Imatinib; Liver fibrosis; Nilotinib; Silymarin; Thioacetamide

Indexed keywords

4 HYDROXYNONENAL; COLLAGEN; GLUTATHIONE; IMATINIB; MALONALDEHYDE; MYELOPEROXIDASE; NILOTINIB; NITRATE; NITRITE; SILYMARIN; SUPEROXIDE DISMUTASE; THIOACETAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DISEASE COURSE; ENZYME ACTIVITY; HISTOPATHOLOGY; LIVER FIBROSIS; LIVER FUNCTION TEST; LIVER INJURY; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT;

ADMINISTRATION, ORAL; ANIMALS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; MALE; OXIDATIVE STRESS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RATS; RATS, WISTAR; SILYMARIN; THIOACETAMIDE;

EID: 79952379738     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2010.00824.x     Document Type: Article

References (44)

1. Pinzani M., Milani S., Herbst H. et al. Expression of platelet-derived growth factor and its receptors in normal human liver and during active hepatic fibrogenesis. Am. J. Pathol. (1996) 148 785-800.
2. Czochra P., Klopcic B., Meyer E. et al. Liver fibrosis induced by hepatic overexpression of PDGF-β in transgenic mice. J. Hepatol. (2006) 45 419-428.
3. Cohen P. Protein kinases - the major drug targets of the twenty-first century? Nat. Rev. Drug Discov. (2002) 1 309-315.
4. Buchdunger E., Cioffi L.C., Law D., Stover S., Ohno-Jones B.J., Lydon N.B. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J. Pharmacol. Exp. Ther. (2000) 295 139-145.
5. Druker B.J., Tamura S., Buchdunger E. et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. (1996) 2 561-566.
6. Weisberg E., Manley P.W., Breitenstein W. et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell (2005) 7 129-141.
7. Kantarjian H., Giles F., Wunderle L. et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N. Engl. J. Med. (2006) 354 2542-2551.
8. Van Etten R.A. Cycling, stressed-out and nervous: cellular functions of c-Abl. Trends Cell Biol. (1999) 9 179-186.
9. Sun X., Majumder P., Shioya H. et al. Activation of the cytoplasmic c-Abl tyrosine kinase by reactive oxygen species. J. Biol. Chem. (2000) 275 17237-17240.
10. Kumar S., Bharti A., Mishra N.C. et al. Targeting of the c-Abl tyrosine kinase to mitochondria in the necrotic cell death response to oxidative stress. J. Biol. Chem. (2001) 276 17281-17285.
11. Kumar S., Mishra N., Raina D., Saxena S., Kufe D. Abrogation of the cell death response to oxidative stress by the c-Abl tyrosine kinase inhibitor STI571. Mol. Pharmacol. (2003) 63 276-282.
12. El Jamali A., Valente A.J., Lechleiter J.D. et al. Novel redox-dependent regulation of NOX5 by the tyrosine kinase c-Abl. Free Radic. Biol. Med. (2008) 44 868-881.
13. Daniels C.E., Wilkes M.C., Edens M. et al. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J. Clin. Invest. (2004) 114 1308-1316.
14. Natarajan S.K., Thomas S., Ramamoorthy P. et al. Oxidative stress in the development of liver cirrhosis: a comparison of two different experimental models. J. Gastroenterol. Hepatol. (2006) 21 947-957.
15. Beyer R.E. A rapid biuret assay for protein of whole fatty tissues. Anal. Biochem. (1983) 129 483-485.
16. Ishak K., Baptista A., Bianchi L. et al. Histological grading and staging of chronic hepatitis. J. Hepatol. (1995) 22 696-699.
17. Gascon-Barré M., Huet P.M., Belgiorno J., Plourde V., Coulombe P.A. Estimation of collagen content of liver specimens. Variation among animals and among hepatic lobes in cirrhotic rats. J. Histochem. Cytochem. (1989) 37 377-381.
18. Gerard-Monnier D., Erdelmeier I., Regnard K., Moze-Henry N., Yadan J.C., Chaudiere J. Reactions of 1-methyl-2-phenylindole with malondialdehyde and 4 hydroxyalkenals. Analytical applications to a colorimetric assay of lipid peroxidation. Chem. Res. Toxicol. (1998) 11 1176-1183.
19. Miranda K.M., Espey M.G., Wink D.A. A rapid, simple spectrophotometric method for simultaneous detection of Nitrate and Nitrite. Nitric Oxide (2001) 5 62-71.
20. Schierwagen C., Bylund-Fellenius A.C., Lundberg C. Improved method for quantification of tissue PMN accumulation measured by myeloperoxidase activity. J. Pharmacol. Methods (1990) 23 179-186.
21. Moron M.S., Depierre J.W., Mannervik B. Levels of glutathione, glutathione reductase and glutathione S-transferase activities in rat lung and liver. Biochim. Biophys. Acta (1979) 582 67-78.
22. Marklund S., Marklund G. Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase. Eur. J. Biochem. (1974) 47 469-474.
23. Bataller R., Brenner D.A. Liver fibrosis. J. Clin. Invest. (2005) 115 209-218.
24. Laleman W., Vander Elst I., Zeegers M. et al. A stable model of cirrhotic portal hypertension in the rat: thioacetamide revisited. Eur. J. Clin. Invest. (2006) 36 242-249.
25. Jang J.H., Kang K.J., Kim Y.H., Kang Y.N., Lee I.S. Reevaluation of experimental model of hepatic fibrosis induced by hepatotoxic drugs: an easy, applicable, and reproducible model. Transplant. Proc. (2008) 40 2700-2703.
26. Oztezcan S., Balkan J., Dogru-Abbasoglu S., Cevikbas U., Aykaç-Toker G., Uysal M. Resistance of erythrocytes to lipid peroxidation in cirrhotic rats. Arch. Med. Res. (2005) 36 459-463.
27. Porter W.R., Neal R.A. Metabolism of thioacetamide and thioacetamide S-oxide by rat liver microsomes. Drug Metab. Dispos. (1978) 6 379-388.
28. Chilakapati J., Korrapati M.C., Hill R.A., Warbritton A., Latendresse J.R., Mehendale H.M. Toxicokinetics and toxicity of thioacetamide sulfoxide: a metabolite of thioacetamide. Toxicology (2007) 230 105-116.
29. Lee J.W., Shin K.D., Lee M. et al. Role of metabolism by flavin-containing monooxygenase in thioacetamide-induced immunosuppression. Toxicol. Lett. (2003) 136 163-172.
30. Halliwell B., Gutteridge J.M.C. Free radicals in biology and medicine, Oxford University Press, Oxford, UK, 1999.
31. Pacher P., Beckman J.S., Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol. Rev. (2007) 87 315-424.
32. Prütz W. Hypochlorous acid interactions with thiols, nucleotides, DNA, and other biological substances. Arch. Biochem. Biophys. (1996) 332 110-120.
33. Neef M., Ledermann M., Saegesser H. et al. Oral imatinib treatment reduces early fibrogenesis but does not prevent progression in the long term. J. Hepatol. (2006) 44 167-175.
34. Yoshiji H., Noguchi R., Kuriyama S. et al. Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats. Am. J. Physiol. Gastrointest. Liver Physiol. (2005) 288 907-913.
35. Yoshiji H., Kuriyama S., Noguchi R. et al. Amelioration of liver fibrogenesis by dual inhibition of PDGF and TGF-beta with a combination of imatinib mesylate and ACE inhibitor in rats. Int. J. Mol. Med. (2006) 17 899-904.
36. Day E., Waters B., Spiegel K. et al. Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib. Eur. J. Pharmacol. (2008) 599 44-53.
37. Pradeep K., Mohan C.V., Gobianand K., Karthikeyan S. Silymarin modulates the oxidant-antioxidant imbalance during diethylnitrosamine induced oxidative stress in rats. Eur. J. Pharmacol. (2007) 560 110-116.
38. Kerkelä R., Grazette L., Yacobi R. et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat. Med. (2006) 12 908-916.
39. Mindikoglu A.L., Regev A., Bejarano P.A., Martinez E.J., Jeffers L.J., Schiff E.R. Imatinib mesylate (gleevec) hepatotoxicity. Dig. Dis. Sci. (2007) 52 598-601.
40. Andrés D., Sánchez-Reus I., Bautista M., Cascales M. Depletion of Kupffer cell function by gadolinium chloride attenuates thioacetamide-induced hepatotoxicity. Expression of metallothionein and HSP70. Biochem. Pharmacol. (2003) 66 917-926.
41. Wolf A.M., Wolf D., Rumpold H. et al. The kinase inhibitor imatinib mesylate inhibits TNF-{alpha} production in vitro and prevents TNF-dependent acute hepatic inflammation. Proc. Natl Acad. Sci. U.S.A. (2005) 102 13622-13627.
42. Hägerkvist R., Sandler S., Mokhtari D., Welsh N. Amelioration of diabetes by imatinib mesylate (Gleevec): role of beta-cell NF-kappaB activation and anti-apoptotic preconditioning. FASEB J. (2007) 21 618-628.
43. Salguero Palacios R., Roderfeld M., Hemmann S. et al. Activation of hepatic stellate cells is associated with cytokine expression in thioacetamide-induced hepatic fibrosis in mice. Lab. Invest. (2008) 88 1192-1203.
44. Cao C., Leng Y., Huang W., Liu X., Kufe D. Glutathione peroxidase 1 is regulated by the c-Abl and Arg tyrosine kinases. J. Biol. Chem. (2003) 278 39609-39614.